lefitolimod   Click here for help

GtoPdb Ligand ID: 14710

Synonyms: MGN-1703 | MGN1703
Immunopharmacology Ligand
Compound class: Nucleic acid
Comment: Lefitolimod (MGN-1703) is a CpG oligonucleotide that was intended to act as a Toll-like receptor 9 (TLR9) agonist to stimulate innate and adaptive immunity. It behaves as a double-stem loop immunomodulator, with CpG motifs at both ends.
Click here for help
No information available.
Summary of Clinical Use Click here for help
Lefitolimod (MGN-1703) was progressed as an anti-tumour clinical candidate [2,5-6], and for anti-HIV potential [1,7]. Development of the asset was discontinued in 2020 following failure to demonstrate efficacy in phase 3 oncology studies and the collpase of its originator.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03837756 Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV Phase 2 Interventional University of Aarhus
NCT02077868 Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Phase 3 Interventional Mologen AG
NCT02668770 Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies Phase 1 Interventional M.D. Anderson Cancer Center 4